Estefanía Monturus

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Martine Piccart, Marion Procter, Debora Fumagalli et al. · Journal of Clinical Oncology · 2021 · 359 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer

Martine Piccart, Marion Procter, Debora Fumagalli et al. · Cancer Research · 2020 · 34 citations

Medicine, Oncology, Pharmacology +17

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

Sibylle Loibl, Jacek Jassem, Amir Sonnenblick et al. · Journal of Clinical Oncology · 2024 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · Journal of Clinical Oncology · 2019 · 27 citations

Medicine, Oncology, Pharmacology +16